Voxelotor Neurocognitive Function Study

Summary

This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition Module of executive abilities in pediatric participants (8 to \< 18 years) with SCD.

Timeline

Start

2022-06-24

Primary completion

2022-09-30

Completion

2022-09-30

Drugs

Indications